In this update to the 2012 summary, the current diagnostic and therapeutic approaches to acromegaly are reviewed. The goals of therapy are
to control excess growth hormone (GH) secretion and tumor growth, and to limit, if not reverse, the long-term medical consequences and risk
for premature mortality associated with acromegaly. Surgery is the preferred primary therapeutic option because it can lead to rapid reductions
in GH levels and prevent mass effects from local tumor growth. Use of a somatostatin receptor ligand (SRL) preoperatively to improve surgical
outcomes has not been substantiated. Medical therapy, including SRLs, dopamine agonists, and the GH receptor antagonist pegvisomant, is
used most often in an adjuvant, secondary role for patients in whom surgery has been unsuccessful. Radiation therapy is most commonly
recommended in the setting of failed surgery and lack of adequate control with medical therapy. A role of primary medical therapy for de novo
patients has been proposed, particularly with SRLs. Using a multimodality approach, successful management of the disease and associated
consequences should be achieved in the majority of subjects.
Acromegaly, somatostatin, pegvisomant, pituitary adenoma, cabergoline
Laurence Katznelson, MD, has received research support from Novartis Pharmaceuticals, and is an advisor for Ipsen and Novartis. No funding was received for the
publication of this article
June 10, 2014 Accepted:
November 26, 2014
Laurence Katznelson, MD, 875 Blake Wilbur Drive, Stanford, CA 94305-5821, US. E: LKatznelson@stanford.edu
Acromegaly is an uncommon disorder that, in the vast majority of cases, is the result of a growth hormone (GH)-secreting pituitary adenoma. Because tumors are often macroadenomas at the time of diagnosis, there may be a number of signs and symptoms related to local mass effects, including headache, visual field loss, ophthalmoplegia, and hypopituitarism. Chronic GH and insulin-like growth factor 1 (IGF-1) hypersecretion can lead to soft tissue and bone overgrowth manifestations, medical comorbidities, and accompanying clinical features. Medical comorbidites include arthropathy, cardiomegaly, type 2 diabetes, hypertension, sleep apnea syndrome, and colon polyps. In addition, acromegaly is associated with premature mortality, primarily owing to cardiovascular disease. Appropriate therapy of acromegaly can lead to improvement in these comorbidities and reversal of the premature mortality risk. This current review is an update to the 2012 summary.1
Diagnosis of Acromegaly
The diagnosis of acromegaly begins with a clinical suspicion by the physician that the patient has this disease. Typical physical examination findings include hand and foot enlargement or facial bone enlargement and acral/soft tissue changes. Of note, subjects usually do not present with a chief complaint related to acral growth. In women, the most common presenting complaint is amenorrhea.2
Biochemical testing involves measurement of GH and IGF-1. GH, produced by the somatotroph cells of the pituitary gland in a pulsatile fashion, circulates and stimulates hepatic secretion of IGF-1. In the recent Endocrine Society guidelines on the approach to acromegaly, it was recommended that a serum IGF-1 level be measured in subjects with acral manifestations. Owing to the lack of agreement between assays and the lack of validated normal ranges for IGF-1,3,4 the same assay should be used in the same patient for serial measurement.5 A random GH measurement was not considered useful in diagnosis because of the lack of a well-defined normal or safe range, although a markedly elevated random GH level is certainly consistent with the disease. Additionally, in subjects with elevated or equivocal serum IGF-1 concentrations, the recent acromegaly guidelines recommended confirmation of the diagnosis with a lack of suppression of GH to less than 1 mcg/l following an oral glucose load.6 In a patient with signs and symptoms of acromegaly and an elevated IGF-1 value, an oral glucose tolerance test (OGTT) may not be necessary for diagnosis. In the setting of a clinical suspicion but discordant values, such as an elevated IGF-1 and normal GH value (i.e., suppressible with OGTT), the subject likely has early stage acromegaly.7
After diagnosis of acromegaly, a magnetic resonance imaging (MRI) scan of the sella should be obtained to determine tumor size, location, and invasiveness.6 Visual field testing is performed if the tumor is touching or compressing the optic chiasm. A thorough ophthalmologic examination should be performed if the patient describes diplopia and the tumor is invading the cavernous sinus. Further endocrine testing should be performed to determine general pituitary function and need for hormone replacement therapy.
1. Katznelson L, Diagnosis and management of acromegaly in 2012,
US Endocrinology, 2011;7:121–5.
2. Nabarro JD, Acromegaly, Clin Endocrinol, 1987;26:481–512.
3. Frystyk J, Freda P, Clemmons DR, The current status of IGF-I
assays—a 2009 update, Growth Horm IGF Res, 2010;20:8–18.
4. Pokrajac A, Wark G, Ellis AR, et al., Variation in GH and IGF-I
assays limits the applicability of international consensus criteria
to local practice, Clin Endocrinol, 2007;67:65–70.
5. Katznelson L, Atkinson JL, Cook DM, et al., American Association
of Clinical Endocrinologists medical guidelines for clinical
practice for the diagnosis and treatment of acromegaly-2011
update, Endocr Pract, 2011;17 Suppl. 4:1–44.
6. Katznelson L, Laws ER Jr., Melmed S, et al., Acromegaly: An
Endocrine Society Clinical Practice Guideline, J Clin Endocrinol
7. Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al., Acromegaly with
apparently normal GH secretion: implications for diagnosis and
follow-up, J Clin Endocrinol Metab, 2002;87:3537–42.
8. Rokkas T, Pistiolas D, Sechopoulos P, et al., Risk of colorectal
neoplasm in patients with acromegaly: a meta-analysis, World J
9. Dogan S, Atmaca A, Dagdelen S, et al.,Evaluation of thyroid
diseases and differentiated thyroid cancer in acromegalic
patients, Endocrine, 2014;45:114–21.
10. Starke RM, Raper DM, Payne SC, et al., Endoscopic vs
microsurgical transsphenoidal surgery for acromegaly:
outcomes in a concurrent series of patients using modern
criteria for remission, J Clin Endocrinol Metab, 2013;98:3190–8.
11. Bourdelot A, Coste J, Hazebroucq V, et al., Clinical, hormonal
and magnetic resonance imaging (MRI) predictors of
transsphenoidal surgery outcome in acromegaly, Eur J
12. Jane JA Jr., Starke RM, Elzoghby MA, et al., Endoscopic
transsphenoidal surgery for acromegaly: remission using
modern criteria, complications, and predictors of outcome,
J Clin Endocrinol Metab, 2011;96:2732–40.
13. Nomikos P, Buchfelder M, Fahlbusch R, The outcome of surgery
in 668 patients with acromegaly using current criteria of
biochemical ‘cure’, Eur J Endocrinol, 2005;152:379–87.
14. Karavitaki N, Turner HE, Adams CB, et al., Surgical debulking of
pituitary macroadenomas causing acromegaly improves control
by lanreotide, Clin Endocrinol, 2008;68:970–5.
15. Kim EH, Oh MC, Lee EJ, Kim SH, Predicting long-term remission
by measuring immediate postoperative growth hormone levels
and oral glucose tolerance test in acromegaly, Neurosurg,
2012;70:1106–13; discussion 13.
16. Dina TS, Feaster SH, Laws ER, Jr., Davis DO, MR of the pituitary
gland postsurgery: serial MR studies following transsphenoidal
resection, AJNR Am J Neuroradiol, 1993;14:763–9.
17. Carlsen SM, Lund-Johansen M, Schreiner T, et al., Preoperative
octreotide treatment in newly diagnosed acromegalic patients
with macroadenomas increases cure short-term postoperative
rates: a prospective, randomized trial, J Clin Endocrinol Metab,
18. Mao ZG, Zhu YH, Tang HL, et al., Preoperative lanreotide
treatment in acromegalic patients with macroadenomas
increases short-term postoperative cure rates: a prospective,
randomised trial, Eur J Endocrinol, 2010;162:661–6.
19. Shen M, Shou X, Wang Y, et al., Effect of presurgical long-acting
octreotide treatment in acromegaly patients with invasive
pituitary macroadenomas: a prospective randomized study,
Endocr J, 2010;57:1035–44.
20. Fougner SL, Bollerslev J, Svartberg J, et al., Preoperative
octreotide treatment of acromegaly: long-term results of a
randomised controlled trial, Eur J Endocrinol, 2014;171:229–35.
21. Khan ZH, Rasouli MR, Intubation in patients with acromegaly:
experience in more than 800 patients, Eur J Anaesthesiol,
22. Damjanovic SS, Neskovic AN, Petakov MS, et al., High output
heart failure in patients with newly diagnosed acromegaly,
Am J Med, 2002;112:610–6.
23. Hradec J, Kral J, Janota T, et al., Regression of acromegalic
left ventricular hypertrophy after lanreotide (a slow-release
somatostatin analog), Am J Cardiol, 1999;83:1506–9, A8.
24. Lombardi G, Colao A, Marzullo P, et al., Improvement of left
ventricular hypertrophy and arrhythmias after lanreotideinduced
GH and IGF-I decrease in acromegaly. A prospective
multi-center study, J Endocrinol Invest, 2002;25:971–6.
25. Katznelson L, Drug insight: Primary medical therapy of
acromegaly, Nat Clin Pract Endocrinol Metab, 2006;2:109–17;
quiz following 17.
26. Carmichael JD, Bonert VS, Mirocha JM, Melmed S, The utility of
oral glucose tolerance testing for diagnosis and assessment
of treatment outcomes in 166 patients with acromegaly, J Clin
Endocrinol Metab, 2009;94:523–7.
27. Trainer PJ, Drake WM, Katznelson L, et al., Treatment of
acromegaly with the growth hormone-receptor antagonist
pegvisomant, N Engl J Med, 2000;342:1171–7.
28. van der Lely AJ, Hutson RK, Trainer PJ, et al., Long-term treatment
of acromegaly with pegvisomant, a growth hormone receptor
antagonist, Lancet, 2001;358:1754–9.
29. Melmed S, Medical management of acromegaly – what and
when?, Acta Endocrinol (Copenh), 1993;129 Suppl. 1:13–7.
30. Abs R, Verhelst J, Maiter D, et al., Cabergoline in the treatment
of acromegaly: a study in 64 patients, J Clin Endocrinol Metab,
31. Sandret L, Maison P, Chanson P, Place of cabergoline in
acromegaly: a meta-analysis, J Clin Endocrinol Metab,
32. Cozzi R, Attanasio R, Lodrini S, Lasio G, Cabergoline addition
to depot somatostatin analogues in resistant acromegalic
patients: efficacy and lack of predictive value of prolactin
status, Clin Endocrinol, 2004;61:209–15.
33. Moyes VJ, Metcalfe KA, Drake WM, Clinical use of cabergoline
as primary and adjunctive treatment for acromegaly, Eur J
34. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E,
Dopamine agonists and the risk of cardiac-valve regurgitation,
N Engl J Med, 2007;356:29–38.
35. Colao A, Pivonello R, Rosato F, et al., First-line octreotide-LAR
therapy induces tumour shrinkage and controls hormone excess
in patients with acromegaly: results from an open, prospective,
multicentre trial, Clin Endocrinol, 2006;64:342–51.
36. Freda PU, Katznelson L, van der Lely AJ, et al., Long-acting
somatostatin analog therapy of acromegaly: a meta-analysis,
J Clin Endocrinol Metab, 2005;90:4465–73.
37. Murray RD, Melmed S, A critical analysis of clinically available
somatostatin analog formulations for therapy of acromegaly,
J Clin Endocrinol Metab, 2008;93:2957–68.
38. Caron PJ, Bevan JS, Petersenn S, et al., Tumor shrinkage with
lanreotide Autogel 120 mg as primary therapy in acromegaly:
results of a prospective multicenter clinical trial, J Clin Endocrinol
39. Colao A, Bronstein M, Freda P, et al., Pasireotide versus
octreotide in acromegaly: a head-to-head superiority study,
J Clin Endocrinol Metab, 2014:jc20132480.
40. Ezzat S, Kontogeorgos G, Redelmeier DA, et al., In vivo
responsiveness of morphological variants of growth hormoneproducing
pituitary adenomas to octreotide, Eur J Endocrinol,
41. Colao A, Ferone D, Lastoria S, et al., Prediction of efficacy of
octreotide therapy in patients with acromegaly, J Clin Endocrinol
42. van der Lely AJ, Biller BM, Brue T, et al., Long-term safety of
pegvisomant in patients with acromegaly: comprehensive
review of 1288 subjects in ACROSTUDY, J Clin Endocrinol Metab,
43. Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ,
Conversion of daily pegvisomant to weekly pegvisomant
combined with long-acting somatostatin analogs, in controlled
acromegaly patients, Pituitary, 2011;14:253–8.
44. Castinetti F, Nagai M, Morange I, et al., Long-term results
of stereotactic radiosurgery in secretory pituitary adenomas,
J Clin Endocrinol Metab, 2009;94:3400–7.
45. Frohman LA, Bonert V, Pituitary tumor enlargement in two
patients with acromegaly during pegvisomant therapy, Pituitary,
46. Schreiber I, Buchfelder M, Droste M, et al., Treatment of
acromegaly with the GH receptor antagonist pegvisomant
in clinical practice: safety and efficacy evaluation from the
German Pegvisomant Observational Study, Eur J Endocrinol,
47. Bonert VS, Kennedy L, Petersenn S, et al., Lipodystrophy
in patients with acromegaly receiving pegvisomant, J Clin
Endocrinol Metab, 2008;93:3515–8.
48. Giustina A, Bonadonna S, Bugari G, et al., High-dose
intramuscular octreotide in patients with acromegaly
inadequately controlled on conventional somatostatin analogue
therapy: a randomised controlled trial, Eur J Endocrinol,
49. van der Lely AJ, Bernabeu I, Cap J, et al., Coadministration of
lanreotide Autogel and pegvisomant normalizes IGF1 levels and
is well tolerated in patients with acromegaly partially
controlled by somatostatin analogs alone, Eur J Endocrinol,
50. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment
of acromegaly: is there still a place for radiotherapy? Pituitary,
51. Petrossians P, Borges-Martins L, Espinoza C, et al., Gross total
resection or debulking of pituitary adenomas improves hormonal
control of acromegaly by somatostatin analogs, Eur J Endocrinol,
52. Trainer PJ, Ezzat S, D’Souza GA, et al., A randomized, controlled,
multicentre trial comparing pegvisomant alone with combination
therapy of pegvisomant and long-acting octreotide in patients
with acromegaly, Clin Endocrinol, 2009;71:549–57.
53. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly
management: an update, J Clin Endocrinol Metab, 2009;94:1509–17.
54. Melmed S, Medical progress: Acromegaly, N Engl J Med,
55. Castinetti F, Morange I, Dufour H, et al., Radiotherapy and
radiosurgery in acromegaly, Pituitary, 2009;12:3–10.
56. Petit JH, Biller BM, Coen JJ, et al., Proton stereotactic
radiosurgery in management of persistent acromegaly,
Endocr Pract, 2007;13:726–34.
57. Castinetti F, Taieb D, Kuhn JM, et al., Outcome of gamma
knife radiosurgery in 82 patients with acromegaly: correlation
with initial hypersecretion, J Clin Endocrinol Metab,
58. Jezkova J, Marek J, Hana V, et al., Gamma knife radiosurgery
for acromegaly – long-term experience, Clin Endocrinol,
59. Pollock BE, Jacob JT, Brown PD, Nippoldt TB, Radiosurgery
of growth hormone-producing pituitary adenomas: factors
associated with biochemical remission, J Neurosurg,
60. Ronchi CL, Attanasio R, Verrua E, et al., Efficacy and tolerability
of gamma knife radiosurgery in acromegaly: a 10-year follow-up
study, Clin Endocrinol, 2009;71:846–52.
61. Landolt AM, Haller D, Lomax N, et al., Octreotide may act as a
radioprotective agent in acromegaly, J Clin Endocrinol Metab,
62. Barrande G, Pittino-Lungo M, Coste J, et al., Hormonal and
metabolic effects of radiotherapy in acromegaly: long-term
results in 128 patients followed in a single center, J Clin
Endocrinol Metab, 2000;85:3779–85.
63. Littley MD, Shalet SM, Beardwell CG, et al., Radiationinduced
hypopituitarism is dose-dependent, Clin Endocrinol,
64. Minniti G, Traish D, Ashley S, et al., Risk of second brain tumor
after conservative surgery and radiotherapy for pituitary
adenoma: update after an additional 10 years, J Clin Endocrinol
65. Rowe J, Grainger A, Walton L, et al., Risk of malignancy after
gamma knife stereotactic radiosurgery, Neurosurg, 2007;60:60–5;